natgillin/translations-raw huggingface dataset:
• Kaposi's sarcoma (a cancer of the blood vessels) in patients with acquired immune deficiency syndrome (AIDS) who have very damaged immune systems and extensive sarcoma on the skin, the moist body surfaces or the internal organs; 
• Kaposijevega sarkoma (raka žil) pri bolnikih s sindromom pridobljene imunske pomanjkljivosti (aidsom), ki imajo zelo prizadet imunski sistem in razširjen sarkom na koži, vlažnih telesnih površinah ali notranjih organih;
Caelyx is used on its own for this disease; 
Za to bolezen se zdravilo Caelyx uporablja samostojno;
• multiple myeloma (a cancer of the cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already undergone or are unsuitable for a bone marrow transplant. 
• multiplega mieloma (raka celic v kostnem mozgu) pri bolnikih z napredujočo boleznijo, ki so prejeli najmanj eno drugačno terapijo in so že prestali presaditev kostnega mozga ali zanjo niso primerni.
The CHMP decided that Caelyx's benefits are greater than its risks and recommended that it be given marketing authorisation. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Caelyx večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
For multiple myeloma, adding Caelyx to bortezomib increased the time until the disease got worse from 6.5 to 9.3 months. 
Z dodajanjem zdravila Caelyx k bortezomibu za zdravljenje multiplega mieloma se je čas do poslabšanja bolezni podaljšal s 6,5 na 9,3 meseca.
Caelyx accumulates in areas in the body where the blood vessels have an abnormal shape, such as within tumours, where its action is concentrated. 
Zdravilo Caelyx se kopiči v delih telesa, kjer imajo žile neobičajno obliko, npr. v tumorjih, v katerih se njegovo delovanje skoncentrira.
Caelyx is not recommended for patients whose spleen has been removed. 
Zdravljenje z zdravilom Caelyx ni priporočljivo za bolnike, ki jim je bila odstranjena vranica.
Caelyx should not be used in people who may be hypersensitive (allergic) to doxorubicin hydrochloride or any of the other ingredients. 
Zdravila Caelyx ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) doksorubicinijev klorid ali katero koli drugo sestavino zdravila.
In the treatment of breast cancer, Caelyx was as effective as standard doxorubicin: the time until the disease got worse was around 7.5 months in both groups. 
Zdravilo Caelyx je bilo pri zdravljenju metastatskega raka dojk enako učinkovito kot običajni doksorubicin: čas do poslabšanja bolezni je bil v obeh skupinah približno 7,5 meseca.
Other information about Caelyx 
Druge informacije o zdravilu Caelyx:
In Caelyx, it is contained in ‘pegylated liposomes' (tiny fatty spheres that are coated with a chemical called polyethylene glycol). 
V zdravilu Caelyx se nahaja v „pegiliranih liposomih“ (majhnih maščobnih kroglicah, ki so prevlečene s snovjo, imenovano polietilenglikol).
For AIDS-related Kaposi's sarcoma, the effectiveness of Caelyx was studied in two main studies involving 384 patients, including 77 who had received treatment before. 
Učinkovitost zdravila Caelyx pri z aidsom povezanem Kaposijevem sarkomu so proučevali v dveh glavnih študijah, ki sta vključevali 384 bolnikov, vključno s 77 bolniki, ki so se zdravili že prej.
For the full list of all side effects reported with Caelyx, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Caelyx, glejte navodilo za uporabo.
• advanced ovarian cancer (cancer of the ovary) in women whose previous treatment including a platinum-based anticancer medicine has stopped working; 
• napredovalega raka jajčnikov pri bolnicah, pri katerih predhodno zdravljenje, vključno s platinsko kemoterapijo, ni bilo več uspešno;
Caelyx has been studied in a total of 2,512 patients in seven main studies. 
Zdravilo Caelyx so proučevali v sedmih glavnih študijah, v katere je bilo vključenih skupno 2512 bolnikov.
What is the risk associated with Caelyx? 
Kakšna tveganja so povezana z zdravilom Caelyx?
Why has Caelyx been approved? 
Zakaj je bilo zdravilo Caelyx odobreno?
The active substance in Caelyx, doxorubicin hydrochloride, is a cytotoxic medicine that belongs to the group ‘anthracyclines'. 
Zdravilna učinkovina zdravila Caelyx, doksorubicinijev klorid, je citotoksično zdravilo iz skupine „antraciklinov“.
For multiple myeloma, the effectiveness of the combination of Caelyx and bortezomib was compared with that of bortezomib alone in 646 patients. 
Učinkovitost kombinacije zdravila Caelyx in bortezomiba pri multiplem mielomu so primerjali s samostojno uporabo bortezomiba pri 646 bolnikih.
For ovarian cancer, Caelyx was as effective as topotecan in extending time until the disease got worse. 
Pri raku jajčnikov je bilo zdravilo Caelyx glede podaljšanja časa do poslabšanja bolezni enako učinkovito kot topotekan.
For metastatic breast cancer, Caelyx has been compared with standard doxorubicin in one main study involving 509 women. 
Uporabo zdravila Caelyx pri metastatskem raku dojk so v glavni študiji, v katero je bilo vključenih 509 žensk, primerjali z običajnim doksorubicinom.
For advanced ovarian cancer, Caelyx has been compared with topotecan (another anticancer medicine) in one study involving 474 women who had received platinum-based chemotherapy in the past. 
Uporabo zdravila Caelyx pri napredovalem raku jajčnikov so primerjali s topotekanom (drugim zdravilom proti raku) v študiji, v katero je bilo vključenih 474 žensk, ki so se prej zdravile s platinsko kemoterapijo.
The side effects with Caelyx depend on the type of cancer being treated. 
Neželeni učinki zdravila Caelyx so odvisni od vrste raka, ki se zdravi.
Treatment should be stopped or the dose reduced in patients who experience certain side effects or who have liver problems. 
Pri bolnikih, pri katerih se pojavijo določeni neželeni učinki, in pri tistih, ki imajo težave z jetri, je treba zdravljenje prekiniti ali zmanjšati odmerek.
Caelyx should be given under the supervision of a doctor who is qualified in the use of cytotoxic (cellkilling) medicines. 
Zdravilo Caelyx se sme uporabljati le pod nadzorom zdravnika, ki je usposobljen za dajanje citotoksičnih zdravil (zdravil, ki uničujejo celice).
Caelyx is concentrate to be made up into a solution for infusion (drip into a vein). 
Zdravilo Caelyx je koncentrat za pripravo raztopine za infundiranje (kapalne infuzije v veno).
What is Caelyx? 
Kaj je zdravilo Caelyx?
How has Caelyx been studied? 
Kako je bilo zdravilo Caelyx raziskano?
What is Caelyx used for? 
Za kaj se zdravilo Caelyx uporablja?
How does Caelyx work? 
Kako zdravilo Caelyx deluje?
How is Caelyx used? 
Kako se zdravilo Caelyx uporablja?
Further information on Kineret can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Več informacij o zdravilu Kineret je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The improvement was maintained over a follow-up period of up to 60 months. 
To izboljšanje se je ohranilo v obdobju spremljanja bolnikov do 60 mesecev.
• cryopyrin-associated periodic syndromes (CAPS). 
• s kriopirinom povezanih periodičnih sindromov (CAPS).
In addition levels of amyloid A, a marker of inflammation were also reduced. 
Poleg tega so se znižale tudi ravni amiloida A, označevalca vnetja.
Kineret received a marketing authorisation valid throughout the European Union on 8 March 2002. 
Za zdravilo Kineret je bilo 8. marca 2002 izdano dovoljenje za promet, veljavno po vsej EU.
What is Kineret and what is it used for? 
Kaj je zdravilo Kineret in za kaj se uporablja?
An overview of Kineret and why it is authorised in the EU 
Pregled zdravila Kineret in zakaj je odobreno v EU
Other information about Kineret 
Druge informacije o zdravilu Kineret
What measures are being taken to ensure the safe use of Kineret? 
Kateri ukrepi se izvajajo za zagotovitev varne uporabe zdravila Kineret?
As for all medicines, data on the use of Kineret are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Kineret stalno spremljajo.
Kineret is a medicine that is used to treat: 
Kineret je zdravilo, ki se uporablja za zdravljenje:
What benefits of Kineret have been shown in studies? 
Kakšne koristi zdravila Kineret so se pokazale v študijah?
Patients either received Kineret or another type of medicine, called a DMARD. 
Bolniki so prejemali zdravilo Kineret ali drugo vrsto zdravila, imenovano DMARD.
Side effects reported with Kineret are carefully evaluated and any necessary action is taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Kineret, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
However, because of the way the study was designed, the results were considered insufficient to support the use of the medicine on its own. 
Vendar zaradi načina zasnove študije te ugotovitve ne štejejo kot zadosten dokaz v podporo uporabi tega zdravila kot samostojnega zdravila.
Kineret has been studied in three main studies involving a total of 1,388 patients with rheumatoid arthritis. 
Zdravilo Kineret so raziskovali v treh glavnih študijah, ki so vključevale skupaj 1 388 bolnikov z revmatoidnim artritisom.
The recommended dose of Kineret for rheumatoid arthritis is 100 mg once a day, given at around the same time each day. 
Priporočeni odmerek zdravila Kineret pri revmatoidnem artritisu je 100 mg enkrat na dan, ki se daje vsak dan ob približno istem času.
The injection site should be varied with each dose to avoid discomfort. 
Mesto injiciranja je treba z vsakim odmerkom spremeniti, da bi se izognili neugodju.
Severe disabilities such as deafness and loss of vision may also occur; 
Prav tako lahko pride do resne prizadetosti, kot sta naglušnost in okvara vida;
Results showed a significant and rapid improvement in symptoms, with a fall in average symptom score from 4.5 to 0.8 within 3 days of starting treatment. 
Rezultati so pokazali znatno in hitro izboljšanje simptomov, in sicer je povprečna ocena simptomov v treh dneh po začetku zdravljenja padla s 4,5 na 0,8.
Why is Kineret authorised in the EU? 
Zakaj je bilo zdravilo Kineret odobreno v EU?
The Agency recommended that Kineret be given marketing authorisation. 
Priporočila je, da se zanj izda dovoljenje za promet.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Kineret have been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Kineret upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
• signs and symptoms of rheumatoid arthritis (an immune system disease causing inflammation of the joints) in adults. 
• znakov in simptomov revmatoidnega artritisa (obolenja imunskega sistema, ki povzroča vnetje sklepov) pri odraslih.
Although patients with Still's disease had a higher risk of liver problems, this risk was considered to be outweighed by the medicine's benefits. 
Čeprav so imeli bolniki s Stillovo boleznijo večje tveganje za težave z jetri, je bilo ocenjeno, da koristi zdravila to tveganje odtehtajo.
What are the risks associated with Kineret? 
Kakšna tveganja so povezana z zdravilom Kineret?
Results showed that Kineret was more effective than placebo when used as an add-on to methotrexate. 
Rezultati so pokazali, da je bilo zdravilo Kineret učinkovitejše od placeba, če se je uporabljalo kot dodatek metotreksatu.
Patients were given Kineret at a starting dose of 1 to 2 mg per kg body-weight daily, increased after a month if necessary. 
Bolniki so prejemali zdravilo Kineret v začetnem odmerku 1 do 2 mg na kilogram telesne mase na dan, po mesecu dni pa se je ta odmerek po potrebi povečal.
It blocks the receptors for a chemical messenger in the body called interleukin 1. 
Zavira receptorje za kemični prenašalec v telesu, ki se imenuje interlevkin 1.
The first study included 468 patients, some of whom had taken other medicines for their disease in the past, and who were given either Kineret on its own or placebo. 
V prvo študijo je bilo vključenih 468 bolnikov, od katerih so nekateri v preteklosti jemali druga zdravila proti tej bolezni, v študiji pa so prejemali bodisi zdravilo Kineret kot samostojno zdravilo bodisi placebo.
By attaching to the receptors that interleukin 1 would normally attach itself to, anakinra blocks the activity of interleukin 1, helping to relieve the symptoms of these diseases. 
Anakinra z vezavo na receptorje, na katere se običajno veže interlevkin 1, prepreči delovanje interlevkina 1 in tako ublaži simptome teh bolezni.
In the other two studies, Kineret was used as an add-on to existing treatment including methotrexate: one study, which involved 419 patients, used a range of doses of Kineret that depended on the patient's weight, and the other study, which involved 501 patients, used Kineret at a fixed dose of 100 mg once a day. 
V drugih dveh študijah so zdravilo Kineret uporabili kot dodatek k obstoječemu zdravljenju, ki je vključevalo metotreksat: v prvi študiji, ki je vključevala 419 bolnikov, so uporabili različne odmerke zdravila Kineret glede na telesno maso bolnikov, v drugi študiji, v kateri je sodeloval 501 bolnik, pa so bolniki zdravilo Kineret prejemali v stalnem odmerku 100 mg enkrat na dan.
The active substance in Kineret, anakinra, is a copy of a natural human protein called ‘human interleukin 1 receptor antagonist'. 
Učinkovina v zdravilu Kineret, anakinra, je kopija naravne človeške beljakovine, imenovane „antagonist človeškega receptorja za interlevkin 1“.
Results showed that certain doses of Kineret were more effective than placebo in reducing the symptoms of the disease, measured by the doctor and the patient using the ‘American College of Rheumatology' score, which includes measurements of the number of painful or tender joints, disease activity, pain, disability and levels of C reactive protein in the blood (a marker of inflammation). 
Rezultati so pokazali, da so določeni odmerki zdravila Kineret pri zmanjševanju simptomov bolezni učinkovitejši od placeba, kot sta simptome ocenjevala zdravnik in bolnik na podlagi lestvice ameriškega inštituta za revmatologijo (American College of Rheumatology), ki vključuje merjenje števila bolečih ali občutljivih sklepov, aktivnosti bolezni, bolečine, gibalne nezmožnosti in ravni C-reaktivne beljakovine v krvi (označevalca vnetja).
For Still's disease, three small studies have been carried out. 
Pri bolnikih s Stillovo boleznijo so izvedli tri manjše študije.
The most common side effects with Kineret (which may affect more than 1 patient in 10) are headache, injection site reactions (redness, bruising, pain and inflammation), and increase in blood cholesterol. 
Najpogostejši neželeni učinki zdravila Kineret (ki se lahko pojavijo pri več kot 1 bolniku od 10) so glavobol, reakcije na mestu injiciranja (rdečina, podplutba, bolečina in vnetje) in povišane ravni holesterola v krvi.
A second study in 24 children showed similar results: 67 % had at least a 30% reduction in symptoms after one month compared with 8 % given placebo. 
Druga študija pri 24 otrocih je pokazala podobne rezultate: pri 67 % so se simptomi po enem mesecu zmanjšali za vsaj 30 %, v primerjavi z 8 % tistih, ki so prejemali placebo.
Kineret must not be started in patients who have neutropenia (low levels neutrophils, a type of blood cell that fights infection). 
Zdravilo se ne sme uvesti pri bolnikih z nevtropenijo (nizkimi vrednostmi nevtrofilcev, vrste krvnih celic, ki se borijo proti okužbam).
Kineret should be used with caution in patients who have severely reduced liver function or moderately reduced kidney function. 
Zdravilo Kineret je treba uporabljati previdno pri bolnikih s hudo okvaro delovanja jeter ali zmerno okvaro delovanja ledvic.
The active substance in Kineret, anakinra, is an immunosuppressive medicine (a medicine that reduces the activity of the immune system). 
Učinkovina v zdravilu Kineret, anakinra, je imunosupresivno zdravilo (zdravilo za zaviranje delovanja imunskega sistema).
After one month of treatment, more patients on Kineret (6 out of 12 patients) achieved remission compared with treatment with DMARD (3 out of 10 patients). 
Po enem mesecu zdravljenja je remisijo doseglo več bolnikov, ki so prejemali zdravilo Kineret (6 od 12), kot bolnikov, ki so prejemali DMARD (3 od 10).
For CAPS, Kineret has been studied in one main study involving 43 patients with neonatal-onset multisystem inflammatory disease (NOMID/CINCA syndrome, the most severe form of CAPS). 
Zdravilo Kineret so pri bolnikih, ki imajo s kriopirinom povezane sindrome, proučevali v eni glavni študiji, ki je zajela 43 bolnikov z multisistemsko vnetno boleznijo z začetkom pri novorojenčku (sindrom NOMID/CINCA, najhujša oblika s kriopirinom povezanih sindromov).
All three studies compared the effectiveness of Kineret with that of placebo (a dummy treatment). 
V vseh treh študijah so učinkovitost zdravila Kineret primerjali s placebom (zdravilom brez učinkovine).
Kineret must not be used in people who are hypersensitive (allergic) to anakinra, to any of the other ingredients, or to proteins produced by Escherichia coli (a type of bacterium). 
Zdravila Kineret ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) učinkovino anakinra, katero koli drugo sestavino zdravila ali beljakovine, ki jih tvori Escherichia coli (vrsta bakterije).
It is used in combination with methotrexate (a medicine used to reduce inflammation) in patients who have not responded adequately to methotrexate alone; 
Uporablja se v kombinaciji z metotreksatom (zdravilom za ublažitev vnetja) pri bolnikih z nezadostnim odzivom na metotreksat kot samostojno zdravilo;
Kineret is available as a solution for injection under the skin. 
Zdravilo Kineret je na voljo v obliki raztopine za injiciranje v podkožje.
Kineret can only be obtained with a prescription and treatment should be started and supervised by a doctor who has experience in the treatment of rheumatoid arthritis, CAPS or Still's disease as appropriate. 
Predpisovanje in izdaja zdravila Kineret je le na recept, zdravljenje z njim pa mora uvesti in nadzorovati zdravnik, ki ima izkušnje z zdravljenjem revmatoidnega artritisa, s kriopirinom povezanih sindromov oziroma Stillove bolezni.
CAPS are a group of diseases where patients have a defect in the gene that produces a protein called cryopyrin. 
S kriopirinom povezani sindromi so skupina bolezni, pri kateri imajo bolniki okvaro gena, ki proizvaja beljakovino kriopirin.
In the study using a fixed dose of Kineret, 38% of the patients adding Kineret had at least a 20% reduction in symptoms after six months, compared with 22% of those adding placebo. 
V študiji, v kateri so uporabljali stalni odmerek zdravila Kineret, je bilo pri 38 % bolnikov, ki so kot dodatek prejemali zdravilo Kineret, po šestih mesecih opaženo najmanj 20-odstotno zmanjšanje simptomov, medtem ko je bil pri bolnikih, ki so kot dodatek prejemali placebo, ta delež 22 %.
The European Medicines Agency decided that Kineret's benefits are greater than its risks for the treatment of the signs and symptoms of rheumatoid arthritis in combination with methotrexate, in patients with an inadequate response to methotrexate alone. 
Evropska agencija za zdravila je zaključila, da so koristi zdravila Kineret pri zdravljenju znakov in simptomov revmatoidnega artritisa v kombinaciji z metotreksatom pri bolnikih z nezadostnim odzivom na metotreksat kot samostojno zdravilo večje od z njim povezanih tveganj.
This leads to inflammation in many parts of the body, with symptoms such as fever, rash, joint pain and tiredness. 
Zaradi tega pride do vnetja na številnih delih telesa s simptomi, kot so povišana telesna temperatura, izpuščaji, bolečine v sklepih in utrujenost.
adult patients who also received corticosteroids for their disease. 
Tretjo študijo so izvedli pri 22 odraslih bolnikih, ki so zaradi svoje bolezni prejemali tudi kortikosteroide.
Given the beneficial effect and the fact that there were no new safety concerns, the Agency also considered that the benefits outweighed the risks in patients with CAPS and Still's disease. 
Zaradi ugodnega učinka in dejstva, da ni bilo ugotovljenih nobenih zadržkov glede varnosti, je menila, da tudi pri bolnikih, ki imajo s kriopirinom povezane sindrome ali Stillovo bolezen, koristi zdravila Kineret odtehtajo tveganja.
How is Kineret used? 
Kako se zdravilo Kineret uporablja?
This messenger is produced in high levels in patients with rheumatoid arthritis, causing inflammation of the joints and joint damage, and is also involved in the inflammation associated with CAPS and Still's disease. 
Ta prenašalec pri bolnikih z revmatoidnim artritisom nastaja v velikih količinah, kar povzroča vnetje in poškodbe sklepov, vpleten pa je tudi v proces vnetja, značilnega za s kriopirinom povezane sindrome in Stillovo bolezen.
For the full list of side effects of Kineret, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Kineret, glejte navodilo za uporabo.
In the first study, 11 of 15 children with Still's disease (73 %) had at least a 30% reduction in symptoms after three months treatment with Kineret. 
V prvi študiji so se simptomi po treh mesecih zdravljenja z zdravilom Kineret pri 11 od 15 otrok s Stillovo boleznijo (73 %) zmanjšali vsaj za 30 %.
• Still's disease, a disease causing inflammation of joints as well as rash and fever. 
• Stillove bolezni, tj. bolezni, ki povzroča vnetje sklepov ter izpuščaj in povišano telesno temperaturo.
For CAPS and Still's disease, the dose depends on body weight and for CAPS, on the severity of the condition. 
Pri bolnikih, ki imajo s kriopirinom povezane sindrome ali Stillovo bolezen, je odmerek odvisen od njihove telesne mase in, pri s kriopirinom povezanih sindromih, od resnosti bolezni.
How does Kineret work? 
Kako zdravilo Kineret deluje?
For CAPS and Still's disease, Kineret is used in patients from 8 months of age and weighing at least 10 kg. Kineret contains the active substance anakinra. 
Pri s kriopirinom povezanih sindromih in Stillovi bolezni se zdravilo Kineret uporablja pri bolnikih od 8. meseca starosti naprej, ki tehtajo vsaj 10 kg.
For more information about using Kineret, see the package leaflet or contact your doctor or pharmacist. 
Pri bolnikih s hudo okvaro delovanja ledvic mora zdravnik razmisliti o dajanju zdravila Kineret vsak drugi dan. Za več informacij glede uporabe zdravila Kineret glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
The overall safety was maintained during all cycles. 
Celotna varnost je obdržana v teku vseh ciklusov
Date of first authorisation: 08 April 2016 
Datum prve odobritve: 8. april 2016
10 μg/kg 
10 µg/kg
Ten percent of patients have a mean terminal elimination halflife greater than 100 hours. 
Deset odstotkov bolnikov ima srednji končni eliminacijski razpolovni čas višji od 100 ur.
• At the request of the European Medicines Agency; Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached. 
• ob vsakršni spremembi sistema za obvladovanje tveganj, zlasti kadar je tovrstna sprememba posledica prejema novih informacij, ki lahko privedejo do znatne spremembe razmerja med koristmi in tveganji, ali kadar je ta sprememba posledica tega, da je bil dosežen pomemben mejnik (farmakovigilančni ali povezan z zmanjševanjem tveganja).
• high levels of sugar in the blood or sugar in the urine 
• zvišana koncentracija sladkorja v krvi ali sladkor v urinu
Do not use this medicine after the expiry date which is stated on the vial and carton after ‘EXP'. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na viali in škatli poleg oznake 'EXP'.
• high levels of certain liver enzymes 
• visoke koncentracije nekaterih jetrnih encimov